Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

SELL
$0.52 - $0.91 $6,612 - $11,572
-12,717 Reduced 7.5%
156,938 $83,000
Q1 2023

May 15, 2023

SELL
$0.7 - $1.41 $9,858 - $19,858
-14,084 Reduced 7.67%
169,655 $127,000
Q4 2022

Feb 13, 2023

BUY
$0.97 - $45.0 $41,375 - $1.92 Million
42,655 Added 30.23%
183,739 $218,000
Q3 2022

Nov 14, 2022

BUY
$1.22 - $40.8 $29,921 - $1 Million
24,526 Added 21.04%
141,084 $183,000
Q2 2022

Aug 12, 2022

SELL
$1.15 - $3.34 $434,323 - $1.26 Million
-377,673 Reduced 76.42%
116,558 $186,000
Q1 2022

May 13, 2022

SELL
$2.96 - $7.76 $66,002 - $173,032
-22,298 Reduced 4.32%
494,231 $1.52 Million
Q4 2021

Feb 08, 2022

SELL
$7.4 - $11.66 $9,109 - $14,353
-1,231 Reduced 0.24%
516,529 $3.82 Million
Q3 2021

Nov 15, 2021

SELL
$9.18 - $14.15 $73,880 - $113,879
-8,048 Reduced 1.53%
517,760 $5.98 Million
Q2 2021

Aug 13, 2021

BUY
$8.07 - $12.52 $247,079 - $383,324
30,617 Added 6.18%
525,808 $6.58 Million
Q1 2021

May 12, 2021

SELL
$8.57 - $15.79 $184,220 - $339,421
-21,496 Reduced 4.16%
495,191 $5.13 Million
Q4 2020

Feb 11, 2021

SELL
$5.98 - $12.47 $76,125 - $158,743
-12,730 Reduced 2.4%
516,687 $4.31 Million
Q3 2020

Nov 16, 2020

BUY
$4.65 - $8.73 $204,437 - $383,814
43,965 Added 9.06%
529,417 $3.26 Million
Q2 2020

Aug 14, 2020

BUY
$4.66 - $8.7 $567,597 - $1.06 Million
121,802 Added 33.49%
485,452 $4.04 Million
Q1 2020

May 14, 2020

BUY
$5.05 - $15.01 $3,933 - $11,692
779 Added 0.21%
363,650 $2.19 Million
Q4 2019

Feb 14, 2020

BUY
$6.32 - $19.66 $1.53 Million - $4.77 Million
242,796 Added 202.2%
362,871 $5.04 Million
Q3 2019

Nov 13, 2019

BUY
$8.03 - $14.82 $615,435 - $1.14 Million
76,642 Added 176.46%
120,075 $1.01 Million
Q2 2019

Aug 13, 2019

BUY
$11.88 - $16.94 $515,984 - $735,755
43,433 New
43,433 $575,000

Others Institutions Holding DTIL

About PRECISION BIOSCIENCES INC


  • Ticker DTIL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 110,818,000
  • Market Cap $554M
  • Description
  • Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific ...
More about DTIL
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.